

REMARKS

Claims 7, 11, 14, 16, 17 and 23 have been amended to eliminate multiple dependencies and place the claims in better compliance with U.S. practice.

In view of the above, an early Notice of Allowance is respectfully requested.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7831  
Date: September 10, 2004

  
\_\_\_\_\_  
Gregory D. Ferraro  
Attorney for Applicants  
Reg. No. 36,134

### Abstract of the disclosure

The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular diseases, or conditions associated therewith.